## PATENT COOPERATION TREATY

PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER	ae well	see Form PCT/ISA/220 as, where applicable, item 5 below.		
H27053C4PH	ACTION				
International application No.	International filing date (day/mon	m/year)	(Earliest) Priority Date (day/month/year)		
PCT/EP2004/009337	20/08/2004	<u> </u>	22/08/2003		
Applicant		•			
FOURNIER LABORATORIES IRE	LAND LIMITED				
This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.					
This International Search Report consists	of a total ofs	neets.			
X It is also accompanied by	a copy of each prior art document	cited in this	report.		
Basis of the report     With regard to the language, the	international search was carried or	it on the ha	sis of the international application in the		
language in which it was filed, un	less otherwise indicated under this	item.	от то тапаната арричати п то		
The international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).					
b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, see Box No. I.					
2. Certain claims were found unsearchable (See Box II).					
3. Unity of invention is lacking (see Box III).					
4. With regard to the title,					
-	ubmitted by the applicant.				
1 =	shed by this Authority to read as fo	lows:			
			·		
5. With regard to the abstract,					
<u></u>	submitted by the applicant.				
the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.					
may, within one month fi	rom the date of mailing of this interi	national sea	iron report, submit comments to this Authority.		
6. With regards to the drawings,					
a. the figure of the drawings to be published with the abstract is Figure No.					
as suggested by					
as selected by t	his Authority, because the applican	t failed to su	uggest a figure.		
_ <del>_</del> _ · ·	his Authority, because this figure be	etter charac	terizes the invention.		
b none of the figures is to	be published with the abstract.				

## INTERNATIONAL SEARCH REPORT

International Application No PCT/EP2004/009337

A. CLASSII IPC 7		(31/404 A61K31/40 A61K3 P9/00	31/506		
According to	International Patent Classification (IPC) or to both national of	classification and IPC			
B. FIELDS					
Minimum do IPC 7	cumentation searched (classification system followed by cla $A61K$	ssification symbols)			
	ion searched other than minimum documentation to the exten				
Electronic da	ata base consulted during the international search (name of	data base and, where practical, search terms used	)		
EPO-In	ternal, BIOSIS, WPI Data, PAJ, E	EMBASE			
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, o	of the relevant passages	Relevant to claim No.		
Y .	ZUNZUNEGUI-PASTOR M V ET AL: CANDESARTAN, METFORMIN AND PR COMBINATION ON CARDIOVASCULAR IN A POOR CONTROLED HYPERTENS POPULATION WITH CHRONIC METAL SYNDROME" AMERICAN JOURNAL OF HYPERTENS YORK, NY, US, vol. 14, no. 4, PART 2, April 2001 (2001-04), pages 113A-114A,ABP-253, XP0011287 abstract	RAVASTATIN R RISK FACTORS SIVE BOLIC SION, NEW	1-16		
χ Furt	her documents are listed in the continuation of box C.	Patent family members are listed	in annex.		
Special categories of cited documents:					
	ent defining the general state of the art which is not	or priority date and not in conflict with cited to understand the principle or the	the application but		
considered to be of particular relevance invention  *E* earlier document but published on or after the international 'X* document of particular relevance; the claimed invention			claimed invention		
filing date  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another  •		cannot be considered novel or cannot involve an inventive step when the do	ocument is taken alone		
citatio	on or other special reason (as specified) nent referring to an oral disclosure, use, exhibition or	"Y" document of particular relevance; the cannot be considered to involve an in document is combined with one or m	oventive step when the ore other such docu-		
other	means ent published prior to the international filing date but	ments, such combination being obvious in the art.			
	than the priority date claimed actual completion of the international search	*&* document member of the same patent			
	19 November 2004	02/12/2004			
Name and	mailing address of the ISA	Authorized officer	Authorized officer		
European Patent Office, P.B. 5818 Patentlaan 2 ,NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Trifilieff-Riolo	Trifilieff-Riolo, S		

1

## INTERNATIONAL SEARCH REPORT

International Application No PCT/EP2004/009337

	TO DE DEL EVANT		
C.(Continua Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
Category	Ollation of document, with indicated, inversity of the control of the contr		
Υ	CARLSEN SVEN M ET AL: "Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease" DIABETES RESEARCH AND CLINICAL PRACTICE, vol. 39, no. 1, January 1998 (1998-01), pages 47-54, XP002269504 ISSN: 0168-8227 abstract	1-16	
Y	CARLSEN SVEN M ET AL: "Metformin increases circulating tumour necrosis factor—alpha levels in non-obese non-diabetic patients with coronary heart disease" CYTOKINE, vol. 10, no. 1, January 1998 (1998-01), pages 66-69, XP002269505 ISSN: 1043-4666 abstract	1-16	
A	ALSHEIKH-ALI ALAWI A ET AL: "Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (Thiazolidinediones, Metformin, Sulfonylurea, Insulin, and Acarbose)" AMERICAN JOURNAL OF CARDIOLOGY, vol. 89, no. 11, 1 June 2002 (2002-06-01), pages 1308-1310, XP002269506 ISSN: 0002-9149 the whole document	1-16	

1